Mala Murthy, the Chief Financial Officer of Teladoc Health, Inc. (NYSE:TDOC), recently executed a significant transaction involving the company's common stock. On December 2, Murthy sold 8,783 shares of Teladoc Health stock at an average price of $11.927 per share, resulting in a total sale value of $104,754. The sale comes as Teladoc, currently valued at $1.89 billion, has seen its shares decline about 47% year-to-date according to InvestingPro data.
Prior to this sale, Murthy engaged in a series of transactions on November 29, where she acquired a total of 15,804 shares through the exercise of performance and restricted stock units. These acquisitions did not involve any cash transactions as they were part of her compensation package. InvestingPro analysis indicates that Teladoc is currently trading below its Fair Value, with a "GREAT" overall financial health score.
Following these transactions, Murthy's direct ownership in Teladoc Health amounts to 92,788 shares. This activity is part of her ongoing management of stock holdings in the company, which provides telehealth services. For deeper insights into Teladoc's valuation and 8 additional exclusive ProTips, including analysis of the company's cash flow yield and debt levels, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Teladoc Health has unveiled AI enhancements to its Virtual Sitter solution, designed to increase patient safety in hospitals. The AI-enabled Virtual Sitter can monitor more patients simultaneously, potentially reducing patient falls in hospitals. The technology uses pre-trained algorithms to identify patient movements that could lead to a fall, allowing for prompt intervention by hospital staff. This development is part of Teladoc Health's broader strategy to leverage technology to enhance healthcare experiences and outcomes.
In financial news, Teladoc Health reported a 3% year-over-year decrease in consolidated revenue to $641 million in the third quarter of 2024. However, the Integrated Care segment saw a 2.5% rise in revenue, reaching $384 million. On the other hand, the BetterHelp segment reported a 10% drop in revenue, to $257 million. The company's adjusted EBITDA for the quarter was $83.3 million, down 6% from the previous year.
Goldman Sachs (NYSE:GS) recently initiated coverage on Teladoc Health, assigning a Buy rating to the company's stock based on a positive outlook for Teladoc's integrated care business, particularly its Chronic Care Segment. The firm projects a turnaround in Teladoc's BetterHelp strategy and anticipates the company's adjusted EBITDA will stabilize in 2025. For the fourth quarter, Teladoc estimates Integrated Care revenue to remain flat or rise up to 2.5%, with adjusted EBITDA margins projected between 12.25% and 13.75%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.